Contrarians think it’s new day for Lilly
The trouble-free market approval obtained by Eli Lilly and Co. for a new underarm testosterone treatment brightened the company’s outlook—at least for one of the few optimistic analysts covering the company.
Health Care & Life Sciences
Articles
CNO Financial looking to refinance bank loans
The Carmel-based life and health insurer says it has started discussions with a group of lenders about refinancing $652.1 million in debt.
St. Francis plans $20M medical campus near Greenwood
The project along Indiana 37 will include outpatient facilities and an emergency room.
St. Francis-WellPoint deal is a sign of the times
St. Francis, which operates three Indianapolis-area hospitals, and WellPoint, the giant health insurer, announced this month that they have agreed to jointly form an accountable care organization.
MCGOWAN: Reform’s grandfathering option requires close look
Widely hailed provision of health care reform now raises host of questions.
AHLRICHS: Turn health reform into pragmatic answers
Health reform entrepreneurship could brand Indiana as productive, healthy place for employers to operate.
Health reform tripping up Indiana wellness incentive
Federal health reform will trump an Indiana law that allows health insurers to offer steep discounts to employers with healthy workers and which institute aggressive wellness programs, but experts say other provisions will motivate small firms.
Med school students share their stories
Five students at Indiana University School of Medicine contemplate whether to opt for family practice or a specialty.
Indiana medical students opt for specialties, not family practice
Interest in primary care has fallen off markedly due partly to relatively low pay.
Study: Indianapolis high-priced hospital market
Indianapolis-area hospitals have negotiated reimbursement rates with private health insurers that are two and three times higher than those paid by the federal Medicare program, suggesting the hospitals have the upper hand over insurers, according to a new study.
Clarian grows market share to 40 percent
Clarian Health has been growing faster than its peers in the Indianapolis market the past five years and is now generating healthy margins, according to a report this month by Moody’s Investors Service.
St. Francis hospitals getting Franciscan Alliance name
The Mishawaka-based health system’s move comes after months of consumer research—and six months after rival system Clarian Health said it would change its name to Indiana University Health.
State joins push to protect elderly from financial scams
Indiana doctors may soon check on patients’ financial health as part of a program that teaches health care providers how to spot victims of swindlers.
Dow AgroSciences moves into new research facility
The division of Dow Chemical has a 15-year lease with Indianapolis-based developer Browning Investments on the two-story building near West 96th Street.
Community, Westview hospitals in ‘strategic alliance’ talks
The form an alliance would take is not clear, but Westview looked for additional resources from city’s four major hospital systems.
City approves Beckman Coulter tax abatement
The tax abatement is tied to an expansion in which the company plans to invest $18 million in its Indianapolis operations and add as many as 95 jobs in the next three years.
Q&A
Les Zwirn, executive director of Better Healthcare for Indiana, talked about his group’s progress on promoting community collaborations to improve health and reduce the cost of care in cities around Indiana. BHI is hosting its third health care summit of Indiana community leaders today at Second Presbyterian Church in Indianapolis.
Lilly scores series of small victories
The Indianapolis-based drugmaker finally won FDA approval for its antidepressant Cymbalta to treat chronic pain and fended off a patent challenge to rising-star cancer drug Alimta, but got a ratings downgrade on its debt.
Court upholds Lilly patent on cancer drug Alimta
A U.S. District Court judge on Monday upheld Eli Lilly and Co.’s patent on the cancer drug Alimta, protecting the compound until July 2016. It was a welcome win after a difficult few months for Indianapolis-based Lilly, which is facing a wave of patent expirations in coming years.
Study: Arthritis drug co-developed by Lilly shows promise
Lilly paid $90 million in 2009 to acquire the global rights to the treatment in a bid to beef up its pipeline of medications for autoimmune diseases.